<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190577</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0427</org_study_id>
    <nct_id>NCT03190577</nct_id>
  </id_info>
  <brief_title>Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology</brief_title>
  <acronym>PRE-TRANS</acronym>
  <official_title>Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial amyloid neuropathy due to transthyretin gene mutations (TTR-FAP) is a rare autosomal
      dominant inherited disease resulting in the abnormal multi-system deposition of amyloid
      proteins. These deposits produce a multi-organ disease. AP is usually fatal 10 to 15 years
      after onset of symptoms if untreated. The prevalence of the disease remains still poorly
      understood and usually the search for this pathology is done in a third line of
      investigation. So the average time to diagnosis is extremely long, from 12 to 24 month. Now
      that the investigators have etiological treatment ( famidis (VyndaqelÂ®) and Diflunisal
      (Dolobid)) of this disease, it is essential to be able to detect FAP patients as early as
      possible. With this study, investigator decided to test for TTR mutation all patients
      presented with neuropathy of unknown etiology at the first line of investigation. The goal of
      this study is to evaluate the prevalence of FAP-TTR among neuropathy and defined the best
      strategy to test this population for TTR mutations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the prevalence of TTR amyloidosis</measure>
    <time_frame>inclusion</time_frame>
    <description>number of patients with TTR mutation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify risk factors of carrying TTR mutations amongst those presenting with &quot;unknown aetiology&quot; neuropathy</measure>
    <time_frame>inclusion</time_frame>
    <description>comparison between patient of medical history, alcohol use, familial neuropathy history, age of first symptoms apparition, description of first symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the TTR-FAP cohort</measure>
    <time_frame>inclusion</time_frame>
    <description>medical history, alcohol use, smoking habits, familial neuropathy history, age of first symptoms apparition, description of first symptoms</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Familial Amyloid Neuropathy</condition>
  <condition>Transthyretin Amyloidosis</condition>
  <arm_group>
    <arm_group_label>patients with neuropathy of unknown aetiology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>two 5 ML EDTA tubes of blood will be collected once by patient</description>
    <arm_group_label>patients with neuropathy of unknown aetiology</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient (male and female) aged not more than 90 years old

          -  Patients with neuropathy identified by EDX exam or small fibre neuropathy identified
             from a skin biopsy.

          -  Patients who have undergone the minimal assessment for neuropathy as defined by the
             HAS (French National Health Authority): biological analysis (fasting glucose, CBC,
             liver and renal functions, CRP, pituitary TSH)

          -  Patients belonging to the social security system

          -  Patient who gave written informed consent

        NON-INCLUSION CRITERIA Patients under legal supervision or guardianship Patients with a
        confirmed documented diagnosis of the cause of neuropathy Patients with evidence of Charcot
        Marie Tooth neuropathy: very slowly progressive course, pes cavus.

        Patients who have already been investigated for a TTR mutation Pregnant women Minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YANN PEREON, MD-PHD</last_name>
    <phone>NA (NO FDA)</phone>
    <email>yann.pereon@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ARMELLE MAGOT, MD</last_name>
    <phone>NA (NO FDA)</phone>
    <email>armelle.magot@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>julien Chassereau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivien PAUTOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>STEEVE GENESTET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chd La Roche Sur Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KARINE BOYER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ARMELLE MAGOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud LEPETIT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch Saint Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BENOIT PEGAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch Saint Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie METZGER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transthyretin mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

